Based in North Carolina, BioCryst Pharmaceuticals is a biotechnology company specializing in the discovery of novel, small-molecule medicines administered orally. Their products include RAPIVAB, RAPIACTA, and PERAMIFLU to treat uncomplicated influenza and ORLADEYO for hereditary angioedema. The company is also developing an oral factor D inhibitor and other treatments for complement-mediated diseases and fibrodysplasia ossificans progressiva in Phase II and Phase I clinical trials.